| Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies J Ciccolini, L Dahan, N André, A Evrard, M Duluc, A Blesius, C Yang, ... J Clin Oncol 28 (1), 160-165, 2010 | 145 | 2010 |
| A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier S Sturm, A Günther, B Jaber, P Jordan, N Al Kotbi, N Parkar, Y Cleary, ... British journal of clinical pharmacology 85 (1), 181-193, 2019 | 109 | 2019 |
| DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity CG Yang, J Ciccolini, A Blesius, L Dahan, D Bagarry-Liegey, C Brunet, ... Cancer chemotherapy and pharmacology 67, 49-56, 2011 | 101 | 2011 |
| Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer N Frances, L Claret, R Bruno, A Iliadis Cancer chemotherapy and pharmacology 68, 1413-1419, 2011 | 54 | 2011 |
| Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile C Mercier, C Dupuis, A Blesius, R Fanciullino, CG Yang, L Padovani, ... Cancer chemotherapy and pharmacology 63, 1177-1180, 2009 | 49 | 2009 |
| Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: methods and examples in drug development A Caruso, N Frances, C Meille, A Greiter-Wilke, A Hillebrecht, T Lavé Journal of pharmacological and toxicological methods 70 (1), 73-85, 2014 | 39 | 2014 |
| An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics C Meille, A Iliadis, D Barbolosi, N Frances, G Freyer Journal of pharmacokinetics and pharmacodynamics 35, 619-633, 2008 | 39 | 2008 |
| Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice WF Richter, GJ Christianson, N Frances, HP Grimm, G Proetzel, ... MAbs 10 (5), 803-813, 2018 | 30 | 2018 |
| Combining nonclinical experiments with translational PKPD modeling to differentiate erlotinib and gefitinib MJ Eigenmann, N Frances, G Hoffmann, T Lavé, AC Walz Molecular Cancer Therapeutics 15 (12), 3110-3119, 2016 | 20 | 2016 |
| Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining In Vitro Experiments with Systems … AJ Van De Vyver, T Weinzierl, MJ Eigenmann, N Frances, S Herter, ... Molecular Cancer Therapeutics 20 (2), 357-366, 2021 | 19 | 2021 |
| PKPD modeling of acquired resistance to anti-cancer drug treatment MJ Eigenmann, N Frances, T Lavé, AC Walz Journal of pharmacokinetics and pharmacodynamics 44, 617-630, 2017 | 17 | 2017 |
| Preclinical characterization of a next-generation brain permeable, paradox breaker BRAF inhibitor J Wichmann, C Rynn, T Friess, J Petrig-Schaffland, M Kornacker, C Handl, ... Clinical Cancer Research 28 (4), 770-780, 2022 | 9 | 2022 |
| Translational pharmacokinetic/pharmacodynamic (PK/PD) modeling strategy to support RG6042 dose selection in Huntington’s disease (HD)(S16. 005) PS Ducray, N Frances, K Smart, D Norris, H Kordasiewicz, A Guenther, ... Neurology 92 (15 Supplement), 2019 | 9 | 2019 |
| Novel in vivo and in vitro pharmacokinetic/pharmacodynamic-based human starting dose selection for glofitamab N Frances, M Bacac, K Bray-French, F Christen, H Hinton, E Husar, ... Journal of Pharmaceutical Sciences 111 (4), 1208-1218, 2022 | 8 | 2022 |
| Time-to-event analysis of paclitaxel-associated peripheral neuropathy in advanced non–small-cell lung cancer highlighting key influential treatment/patient factors FW Ojara, A Henrich, N Frances, W Huisinga, N Hartung, M Joerger, ... Journal of Pharmacology and Experimental Therapeutics 375 (3), 430-438, 2020 | 6 | 2020 |
| A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non‐small cell lung cancer patients FW Ojara, A Henrich, N Frances, YM Nassar, W Huisinga, N Hartung, ... CPT: Pharmacometrics & Systems Pharmacology 12 (11), 1714-1725, 2023 | 4 | 2023 |
| Preclinical InVivo data integrated in a modeling network informs a refined clinical strategy for a CD3 T-Cell bispecific in combination with anti-PD-L1 J Sánchez, V Nicolini, L Fahrni, I Waldhauer, AC Walz, C Jamois, ... The AAPS Journal 24 (6), 106, 2022 | 3 | 2022 |
| Progress in strategies for dosage regimen individualization H Marouani, C Woloch, S Benay, N Frances, A Iliadis Current Topics in Medicinal Chemistry 12 (15), 1669-1677, 2012 | 2 | 2012 |
| A model‐based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno‐oncology J Sánchez, C Claus, R Albrecht, BC Gaillard, J Marinho, C McIntyre, ... CPT: Pharmacometrics & Systems Pharmacology 12 (11), 1804-1818, 2023 | 1 | 2023 |
| The SMN2 Splicing Modifier RG7916 Induces a Dose-Dependent Increase of Full Length SMN2 mRNA S Sturm, A Gunther, S Nave, P Jordan, N Al Kotbi, N Parkar, Y Cleary, ... Annals of Neurology 80, S292-S293, 2016 | 1 | 2016 |
